ACRS vs IDXX · rev $3.6M vs P/E 40, rev $2.36B
Aclaris Therapeutics Inc (ACRS) versus IDEXX Laboratories Inc (IDXX) — a side-by-side from cached financials, not a winner call.
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Latest reported ACRS revenue for 2026-06-30 was $3.6M. Net income was -$41.3M. Revenue was up 81.6% from 2026-03-31 to 2026-06-30. ACRS currently screens at market cap $615.9M.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
ACRS currently screens at market cap $615.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Not investment advice. Open the ACRS and IDXX stock pages for the full models.
Not investment advice.